01AbbVie reported Q3 2026 EPS of $3.82, exceeding the consensus estimate of $3.77 by $0.05 per share.
02Revenue reached $17.4B, matching analyst estimates for the quarter.
03The stock trades at $297.90 with a $410.1B market capitalization following the earnings release.
04AbbVie beat estimates in Q3 2026 and Q4 2025, but missed in Q2 2026 by 3.2% and Q1 2026 by 0.4%.
Earnings Results
AbbVie (NYSE:ABBV) reported quarterly earnings results on October 30, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $3.82, beating the consensus estimate of $3.77 by $0.05 per share. Revenue came in at $17.4B, beating the estimate of $17.4B.
Company Overview
AbbVie's stock moved following the earnings release. The stock currently trades at $297.90 with a market capitalization of $410.1B.
AbbVie's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking AbbVie should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.